BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

Imugene Limited (IMU.AX) Capital Raising Complete


10/23/2013 1:31:47 PM

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

Melbourne, 23 October 2013: Australian drug development and pharmaceutical company Imugene (ASX.IMU) advises that it has completed a A$2.5 million capital raise via the placement of 250 million shares at $0.01 per share to sophisticated investor clients of Forrest Capital to raise A$2.5 million before costs. Proceeds of the placement will be applied towards the Biolife acquisition, the existing business of the Company and general working capital.

85 million shares of the placement will be issued immediately using the Company's share issue capacity under ASX Listing Rule 7.1 and 7.1A, with the balance subject to shareholder approval.

In addition, and subject to shareholder approval, Executive Director, Dr. Nick Ede will personally invest $100,000 by subscribing for 10,000,000 Imugene shares at $0.01 per share. Shareholder approval will be sought prior to the issue of shares to Dr. Ede in accordance with ASX Listing 10.11.

A Notice of Meeting will be sent to shareholders as soon as possible.

Contact :

Dr Nick Ede

Executive Director, Imugene

Tel: +61 400 642 254

Email: nede[at]imugene.com

Media contact:

Dr Douglas Pretsell

College Hill

Tel: +61 3 9657 0706

Email: douglas.pretsell[at]collegehill.com

Help employers find you! Check out all the jobs and post your resume.


Read at BioSpace.com

   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES